Deerfield Management

Latest fund size

$600M

Announced

May 5, 2025

Global HQ

United States

Members only

Check size

$5M - $50M

Members only

Stage focus

Seed, Series A, Series B, Growth (Series C+)

Members only

Regions of investment

North America, Europe

Members only

About

Deerfield Management Company is a New York City-based investment firm founded with a mission to advance healthcare and improve global health outcomes. With a robust in-house ecosystem and a multidisciplinary team, Deerfield operates at the intersection of venture capital, scientific research, and strategic innovation. The firm collaborates with academic institutions, startups, and corporations to fund, incubate, and scale solutions that drive meaningful transformation across the healthcare landscape. Its approach blends scientific rigour, operational support, and capital access to help breakthrough therapeutics and technologies reach patients faster.

Contact info

Website

T: (+1) 212-551-1600

F: (+1) 212-599-3075

Investment and Partnership inquiries to Karen Heidelberger: Karenh1@deerfield.com

Deerfield Foundation inquiries to Mark Veich: Mveich@deerfieldfoundation.org

CURE. inquiries: info@wewillcure.com

Members only

Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.

Investment focus

Deerfield invests across the healthcare continuum, with an emphasis on therapeutics, digital health, care delivery models, and AI-driven technologies.

The firm supports early-stage through growth-stage ventures that can reshape medical paradigms, improve care access and efficiency, and enhance health system performance. Particular attention is given to companies leveraging machine learning, drug development innovation, and platform technologies with high potential for impact.

Members only

What the fund looks for in founders and which sectors it backs.

Fund

In May 2025, Deerfield Management announced the close of its third dedicated healthcare venture fund, the Deerfield Healthcare Innovations Fund III, with over $600 million in committed capital. The fund is designed to fuel innovation in therapeutics, medical technology, healthcare delivery, and AI-powered solutions.

It continues Deerfield’s strategy of combining scientific and operational excellence with patient-centric investment. Fund III is bolstered by Deerfield’s deep network, including partnerships with 29 leading research institutions and nine industry collaborators.

A unique aspect of the fund is its philanthropic component - allocating a portion of profits not distributed to limited partners to the Deerfield Foundation, which focuses on improving child health globally.

This fund extends Deerfield’s commitment to driving innovation while fostering long-term, systemic improvements in global healthcare delivery.

Members only

Fund size, LPs and track record.

Other information

Leadership

Deerfield is led by James Flynn, Managing Partner, who has overseen the firm’s transformation into one of the leading healthcare-focused investment platforms. The firm’s leadership includes seasoned professionals with backgrounds in clinical medicine, biostatistics, data science, drug development, and venture capital.

‍

‍

Investment Strategy

The firm deploys capital through a combination of direct investments, collaborative research agreements, and internally incubated ventures. Its in-house teams - such as Deerfield Discovery and Development (3DC) and Deerfield Intelligence - bring together scientists, engineers, and business leaders to rigorously evaluate and operationalize novel healthcare innovations.

Deerfield also operates Cure, a healthcare innovation campus in New York City that provides lab facilities, community space, and infrastructure for growing healthtech companies. This hands-on, ecosystem-driven approach distinguishes Deerfield as a long-term partner for companies pursuing breakthrough solutions in healthcare.

‍

‍

Notable Investments

Deerfield’s portfolio spans hundreds of healthcare innovations and ventures, including investments in high-impact therapeutic companies, AI-powered diagnostics, and health delivery platforms.

Many of these startups were launched or scaled in partnership with Deerfield's internal teams or through its university-backed initiatives. While specific names from Fund III are not yet disclosed, the firm has a long history of backing companies that go on to achieve FDA approvals, commercial success, and global impact.

‍

Members only

Leadership, investment strategy, notable investments and exits.

Unlock this fund's full profile

✓ Emails and LinkedIn for the team

✓ Check size, stage focus and regions of investment

✓ LPs, notable investments and exits

✓ Search and filters across 700+ funds

Unlock this fund and 700+ more

From $14/month, billed yearly. Cancel any time.

Read the newsletter that top VCs and founders keep in their inbox.

Join the weekly newsletter